What is the Market's View on Curis, Inc. (CRIS) Stock's Price and Volume Trends Tuesday?

Curis, Inc. (CRIS) stock is higher by 41.25% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Curis, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRIS!

See Full CRIS Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With CRIS Stock Today?

Curis, Inc. (CRIS) stock is trading at $11.95 as of 12:53 PM on Tuesday, Nov 28, a gain of $1.05, or 9.63% from the previous closing price of $10.90. The stock has traded between $10.72 and $12.54 so far today. Volume today is high. So far 241,980 shares have traded compared to average volume of 106,515 shares. To screen for more stocks like Curis, Inc. click here.

More About Curis, Inc.

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. Click Here to get the full Stock Report for Curis, Inc. stock.